Developer docs
API playgroundTry for free, no card

Search company profiles

J2H Biotech

Full company profile

uuid00036i9

Namestring
J2H Biotech
Legal namestring
J2H Biotech Inc.
Websiteurl
j2hbio.com
Company typeenum
Private
Founded yearint
2014
Descriptiontext

J2H Biotech is a South Korean clinical-stage biopharmaceutical company founded in 2014 that develops small-molecule therapeutics for rare and intractable diseases. The company operates a dual-engine business combining proprietary drug discovery and development with GMP-certified API manufacturing and CDMO services. Its R&D engine is built around the OPTIFLEX® platform, an AI-driven drug discovery system that uses multidimensional scoring of physicochemical and pharmacokinetic properties to accelerate lead identification, with sub-platforms OPTIFLEX®-SM for small molecules and OPTIFLEX®-TPD for targeted protein degradation (TPD) drugs aimed at undruggable targets.

The company's clinical pipeline spans seven candidates addressing metabolic-associated steatohepatitis (J2H-1702, a selective 11β-HSD1 inhibitor that completed Phase 2a in December 2025), idiopathic pulmonary fibrosis (J2H-2302, a multi-kinase inhibitor partnered with SK chemicals), non-small cell lung cancer (J2H-2002, an EGFR degrader via TPD), multiple sclerosis (J2H-1801, IND-approved for Phase 1), inflammatory bowel disease (J2H-1802), atopic dermatitis and osteoarthritis (J2H-2104), and solid tumors (J2H-2301). The company monetizes through a B2B sales-led model: licensing and co-development deals with pharmaceutical partners — with SK chemicals as the anchor investor-customer since 2021 — CDMO contracts at its two manufacturing facilities (the GMP-certified Ansan Plant and the multi-purpose Asan Plant with nine reactors ranging 200L to 5,000L), and proprietary API product sales including Donepezil hydrochloride, Entresto new salts, Gemigliptin new salts, L-Arginine hydrochloride, and Eltrombopag olamine.

J2H is headquartered in Suwon with an additional development R&D center in Seongnam, and has been recognized by Korean government programs including Preliminary Unicorn designation (2019), Excellent Corporate R&D Center (2021), Inno-Biz certification, and selection for the National Project on Global Rare Disease Diagnosis and Treatment Development with approximately 6 billion KRW in funding support. The company has raised roughly $37 million cumulatively across disclosed equity rounds and holds 57 Korean patent applications, 17 Korean grants, 24 PCT applications, and 35 international grants. Revenue figures are not publicly disclosed.

Short descriptiontext

J2H Biotech is a South Korean clinical-stage biopharmaceutical company developing small-molecule therapeutics for rare and intractable diseases using its proprietary OPTIFLEX® AI-driven drug discovery platform, while operating GMP-certified API manufacturing and CDMO services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeongnam, South Korea
HQ citystring
Seongnam
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule drug discovery, contract development manufacturing, rare disease therapeutics, API manufacturing services, targeted protein degradation
Industry5 codes
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code4 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Drug Discovery and CDMO Services
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1CDMO/Contract Manufacturing Services
TypeProfessional Services
Description

J2H Biotech operates two GMP-certified manufacturing facilities (Ansan and Asan plants) providing contract development and manufacturing organization (CDMO) services to pharmaceutical clients. Services include API production, patent circumvention APIs, clinical trial material manufacturing, and commercial-scale production.

j2hbio.com
2Drug Development Licensing and Co-development
TypeLicensing Royalties
Description

The company generates potential licensing revenue through co-development partnerships with pharmaceutical companies. J2H develops drug candidates through Phase 2a and beyond, with licensing or co-development deals with partners such as SK chemicals, with the goal of out-licensing programs or receiving milestone payments.

j2hbio.com
3API Product Sales
TypeHardware Sales
Description

The company develops and produces proprietary Active Pharmaceutical Ingredients including Donepezil hydrochloride, Entresto new salts, Gemigliptin new salts, L-Arginine hydrochloride, and Eltrombopag olamine for commercial supply to pharmaceutical clients.

j2hbio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

J2H Biotech is a bio-venture company that develops small-molecule drugs for the treatment of rare and intractable diseases using its proprietary OPTIFLEX AI-driven drug discovery platform, with seven candidates across MASH, IPF, NSCLC, multiple sclerosis, IBD, atopic dermatitis, osteoarthritis, and solid tumors. The company also operates two manufacturing facilities — a GMP-certified Ansan Plant for high-value API production and a multi-purpose Asan Plant — providing API manufacturing, patent circumvention, and CDMO (contract development and manufacturing organization) services to pharmaceutical clients under co-development and licensing partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • J2H-1702 (MASH candidate): MRI-PDFF liver fat content decreased in dose-dependent and statistically significant manner vs. placebo; ALT liver function improved significantly in two high-dose groups; MRE-based liver stiffness decreased 30% or more in 10% of drug-treated patients vs. 0% in placebo; fibrosis biomarkers (Pro-C3, TIMP-1, PIIINP, HA, ELF) consistently decreased across all doses.
+2 more records
Product overview1 text field

J2H Biotech operates as a dual-engine business with innovative drug R&D and API/CDMO manufacturing. The R&D division develops small-molecule oral therapeutics for rare and incurable diseases using the proprietary OPTIFLEX® AI-driven platform, spanning seven drug candidates (J2H-1702, J2H-2302, J2H-2002, J2H-1801, J2H-1802, J2H-2104, J2H-2301) across MASH, IPF, NSCLC, multiple sclerosis, IBD, atopic dermatitis, osteoarthritis, and solid tumors. The API division operates two manufacturing facilities: GMP-certified Ansan Plant for high-value API production and CDMO services, and Asan Plant for multi-purpose chemical synthesis and CDMO business. The company's most advanced pipeline, J2H-1702 for MASH, has completed Phase 2a clinical trials.

Product and service3 records
1CDMO (Contract Development and Manufacturing Organization) Services
CategoryPharmaceutical contract manufacturing services
Description

Contract development and manufacturing organization services including API production, patent circumvention APIs, clinical trial material manufacturing, commercial-scale production, OEM, ODM, and toll manufacturing for pharmaceutical clients. Production is supported by GMP-certified Ansan Plant and Asan Plant reactors ranging from 200L to 5,000L (G/L & SUS), dryers, filters, and milling systems, with CMC documentation support.

2Proprietary Active Pharmaceutical Ingredient (API) Products
CategoryActive pharmaceutical ingredient products
Description

Proprietary Active Pharmaceutical Ingredients developed and produced at J2H Biotech's API Division for commercial supply to pharmaceutical clients, including Donepezil hydrochloride, Entresto new salts, Gemigliptin new salts, L-Arginine hydrochloride, and Eltrombopag olamine. The company also holds a granted patent on the novel crystalline free base form of Tenofovir Disoproxil, which J2H successfully defended against invalidation challenges from 11 competing pharmaceutical companies.

3Drug Development, Co-Development, and Out-Licensing Programs
CategoryPharmaceutical drug development and licensing programs
Description

Drug development programs supporting co-development partnerships and out-licensing of small-molecule drug candidates for rare and intractable diseases. J2H Biotech develops candidates through Phase 2a and beyond, then enters licensing or co-development agreements with pharmaceutical partners such as SK chemicals for assets including J2H-1702 (MASH), J2H-2302 (IPF), J2H-2002 (NSCLC), J2H-1801 (multiple sclerosis), J2H-1802 (IBD), J2H-2104 (atopic dermatitis/osteoarthritis), and J2H-2301 (solid tumors).

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2026-06-23
Description

KHIDI organized partnering sessions between Korean biotechnology firms including J2H Biotech and AstraZeneca experts at the BIO International Convention in San Diego under Project NOVA. KHIDI plans to support follow-up communication to facilitate joint R&D, building on the K-Biopharma Next Bridge initiative launched with Korea's Ministry of Health and Welfare.

2SK chemicals (SK케미칼)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-26
Description

SK chemicals and J2H Biotech signed a memorandum of understanding to collaborate on new drug development focusing on MASH and IPF treatments. Both companies agreed to share research results and review data to determine the potential for joint development and commercialization. SK chemicals has been collaborating with J2H since 2021 through platform-based joint research for candidate discovery and strategic equity investment. The partnership expanded to potential co-development of J2H-1702 (MASH, Phase 2a completed) and J2H-2302 (IPF, preclinical).

koreabiomed.com
3Aptis (앱티스)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-22
Description

Aptis and J2H Biotech entered a collaboration for ADC (Antibody-Drug Conjugate) new drug co-development. This partnership combines Aptis's ADC platform capabilities with J2H's small molecule and TPD technologies for innovative oncology drug development.

j2hbio.com
4Samsung Seoul Hospital
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-15
Description

Samsung Seoul Hospital and J2H Biotech entered a joint development agreement for BK virus (BKV) treatment targeting kidney transplant recipients and immunocompromised patients. This collaboration leverages clinical expertise and patient access to advance novel therapeutics for a rare, difficult-to-treat viral infection.

hankyung.com
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2017-07-03
Description

J2H Biotech partnered with Huons for the development of a novel crystalline free base form of Tenofovir Disoproxil (generic version of Gilead's Viread). J2H provided the novel crystal form patent and the parties jointly conducted clinical studies, filing for product approval on the PMS expiration date. J2H successfully defended the patent against challenges from 11 competing pharmaceutical companies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

South Korean biotech with a proprietary ADC and TPD platform (ConjuAll, TetraMAV) developing oncology therapeutics. Directly comparable to J2H on small-molecule discovery platform, TPD/ADC capability, and Korean biotech scale.

TypeDirect peer
Description

Major South Korean pharma with deep small-molecule pipelines and in-house CDMO/API manufacturing across multiple plants. Comparable to J2H in combining proprietary small-molecule R&D with integrated GMP manufacturing and B2B pharmaceutical services.

3Bridge Biotherapeutics
TypeDirect peer
Description

South Korean clinical-stage biotech developing small-molecule therapies for fibrotic and inflammatory diseases, notably IPF. Closely comparable to J2H in indication overlap (IPF) and small-molecule, Korean clinical-stage biotech profile.

4Gtreebio
TypeDirect peer
Description

South Korean biotech developing small-molecule therapeutics for ophthalmology and fibrotic diseases, co-founded by J2H's current CSO. Comparable to J2H on small-molecule modality, Korean biotech scale, and rare/intractable disease focus.

TypeDirect peer
Description

South Korean clinical-stage biotech focused on small-molecule oncology drug development. Comparable to J2H on small-molecule discovery, oncology pipeline programs (e.g., solid tumor candidates), and Korean clinical-stage biotech positioning.

TypeBroad incumbent
Description

Large South Korean pharmaceutical company with established small-molecule pipelines and active CDMO/API business. Comparable to J2H's CDMO plus proprietary drug development dual model, but at substantially greater scale and broader scope.

TypeDirect peer
Description

South Korean biotech with molecular diagnostics and bio-therapeutic development plus in-house manufacturing. Comparable to J2H on combined R&D and manufacturing capabilities within a Korean mid-cap biotech profile.

TypeBroad incumbent
Description

Mid-to-large South Korean pharmaceutical company with small-molecule development and CDMO operations. Comparable to J2H on the integrated pharma-plus-CDMO structure, though operating at a much larger and more diversified scale.

9Dong-A ST
TypeBroad incumbent
Description

Established South Korean pharmaceutical company with proprietary small-molecule drug pipelines and specialty manufacturing. Comparable to J2H on Korean pharma with proprietary small-molecule R&D plus manufacturing infrastructure, though at much greater commercial scale.

10Aptis (partner)
TypeEmerging player
Description

South Korean biotech with ADC platform capabilities partnered with J2H on ADC co-development. Comparable to J2H as a Korean emerging biotech collaborating on next-generation oncology modalities, with adjacent rather than directly overlapping technology.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability1 record

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors18 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

J2H Biotech

Pharmaceutical Drug Discovery and CDMO Servicesj2hbio.com

J2H Biotech is a South Korean clinical-stage biopharmaceutical company developing small-molecule therapeutics for rare and intractable diseases using its proprietary OPTIFLEX® AI-driven drug discovery platform, while operating GMP-certified API manufacturing and CDMO services.

What J2H Biotech does

J2H Biotech is a South Korean clinical-stage biopharmaceutical company founded in 2014 that develops small-molecule therapeutics for rare and intractable diseases. The company operates a dual-engine business combining proprietary drug discovery and development with GMP-certified API manufacturing and CDMO services. Its R&D engine is built around the OPTIFLEX® platform, an AI-driven drug discovery system that uses multidimensional scoring of physicochemical and pharmacokinetic properties to accelerate lead identification, with sub-platforms OPTIFLEX®-SM for small molecules and OPTIFLEX®-TPD for targeted protein degradation (TPD) drugs aimed at undruggable targets.

The company's clinical pipeline spans seven candidates addressing metabolic-associated steatohepatitis (J2H-1702, a selective 11β-HSD1 inhibitor that completed Phase 2a in December 2025), idiopathic pulmonary fibrosis (J2H-2302, a multi-kinase inhibitor partnered with SK chemicals), non-small cell lung cancer (J2H-2002, an EGFR degrader via TPD), multiple sclerosis (J2H-1801, IND-approved for Phase 1), inflammatory bowel disease (J2H-1802), atopic dermatitis and osteoarthritis (J2H-2104), and solid tumors (J2H-2301). The company monetizes through a B2B sales-led model: licensing and co-development deals with pharmaceutical partners — with SK chemicals as the anchor investor-customer since 2021 — CDMO contracts at its two manufacturing facilities (the GMP-certified Ansan Plant and the multi-purpose Asan Plant with nine reactors ranging 200L to 5,000L), and proprietary API product sales including Donepezil hydrochloride, Entresto new salts, Gemigliptin new salts, L-Arginine hydrochloride, and Eltrombopag olamine.

J2H is headquartered in Suwon with an additional development R&D center in Seongnam, and has been recognized by Korean government programs including Preliminary Unicorn designation (2019), Excellent Corporate R&D Center (2021), Inno-Biz certification, and selection for the National Project on Global Rare Disease Diagnosis and Treatment Development with approximately 6 billion KRW in funding support. The company has raised roughly $37 million cumulatively across disclosed equity rounds and holds 57 Korean patent applications, 17 Korean grants, 24 PCT applications, and 35 international grants. Revenue figures are not publicly disclosed.

J2H Biotech firmographics

Firmographics
Name
J2H Biotech
Legal name
J2H Biotech Inc.
Website
https://j2hbio.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
11–50 employees
Short description
J2H Biotech is a South Korean clinical-stage biopharmaceutical company developing small-molecule therapeutics for rare and intractable diseases using its proprietary OPTIFLEX® AI-driven drug discovery platform, while operating GMP-certified API manufacturing and CDMO services.
Ownership category
akta.pro rank

J2H Biotech industry classification

Industry
Product category
Pharmaceutical Drug Discovery and CDMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAHAB
Small-Molecule API Commercial Manufacturing
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAM
Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAGAL
GMP Quality, Validation & Regulatory Support (GMP/CSV/Qualification)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Small molecule drug discovery
  • Contract development manufacturing
  • Rare disease therapeutics
  • API manufacturing services
  • Targeted protein degradation

Where J2H Biotech is headquartered

Location

Headquarters

HQ city
Seongnam
HQ country
South Korea
HQ region
Asia

Offices4 records

Markets served

J2H Biotech business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. CDMO/Contract Manufacturing Services: J2H Biotech operates two GMP-certified manufacturing facilities (Ansan and Asan plants) providing contract development and manufacturing organization (CDMO) services to pharmaceutical clients. Services include API production, patent circumvention APIs, clinical trial material manufacturing, and commercial-scale production.
  2. Drug Development Licensing and Co-development: The company generates potential licensing revenue through co-development partnerships with pharmaceutical companies. J2H develops drug candidates through Phase 2a and beyond, with licensing or co-development deals with partners such as SK chemicals, with the goal of out-licensing programs or receiving milestone payments.
  3. API Product Sales: The company develops and produces proprietary Active Pharmaceutical Ingredients including Donepezil hydrochloride, Entresto new salts, Gemigliptin new salts, L-Arginine hydrochloride, and Eltrombopag olamine for commercial supply to pharmaceutical clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

J2H Biotech product offering

Product offering

Core offering

J2H Biotech is a bio-venture company that develops small-molecule drugs for the treatment of rare and intractable diseases using its proprietary OPTIFLEX AI-driven drug discovery platform, with seven candidates across MASH, IPF, NSCLC, multiple sclerosis, IBD, atopic dermatitis, osteoarthritis, and solid tumors. The company also operates two manufacturing facilities — a GMP-certified Ansan Plant for high-value API production and a multi-purpose Asan Plant — providing API manufacturing, patent circumvention, and CDMO (contract development and manufacturing organization) services to pharmaceutical clients under co-development and licensing partnerships.

Product overview

J2H Biotech operates as a dual-engine business with innovative drug R&D and API/CDMO manufacturing. The R&D division develops small-molecule oral therapeutics for rare and incurable diseases using the proprietary OPTIFLEX® AI-driven platform, spanning seven drug candidates (J2H-1702, J2H-2302, J2H-2002, J2H-1801, J2H-1802, J2H-2104, J2H-2301) across MASH, IPF, NSCLC, multiple sclerosis, IBD, atopic dermatitis, osteoarthritis, and solid tumors. The API division operates two manufacturing facilities: GMP-certified Ansan Plant for high-value API production and CDMO services, and Asan Plant for multi-purpose chemical synthesis and CDMO business. The company's most advanced pipeline, J2H-1702 for MASH, has completed Phase 2a clinical trials.

Differentiator

Problem solved

Functional benefit

Products and services

  • CDMO (Contract Development and Manufacturing Organization) Services Contract development and manufacturing organization services including API production, patent circumvention APIs, clinical trial material manufacturing, commercial-scale production, OEM, ODM, and toll manufacturing for pharmaceutical clients. Production is supported by GMP-certified Ansan Plant and Asan Plant reactors ranging from 200L to 5,000L (G/L & SUS), dryers, filters, and milling systems, with CMC documentation support.
  • Proprietary Active Pharmaceutical Ingredient (API) Products Proprietary Active Pharmaceutical Ingredients developed and produced at J2H Biotech's API Division for commercial supply to pharmaceutical clients, including Donepezil hydrochloride, Entresto new salts, Gemigliptin new salts, L-Arginine hydrochloride, and Eltrombopag olamine. The company also holds a granted patent on the novel crystalline free base form of Tenofovir Disoproxil, which J2H successfully defended against invalidation challenges from 11 competing pharmaceutical companies.
  • Drug Development, Co-Development, and Out-Licensing Programs Drug development programs supporting co-development partnerships and out-licensing of small-molecule drug candidates for rare and intractable diseases. J2H Biotech develops candidates through Phase 2a and beyond, then enters licensing or co-development agreements with pharmaceutical partners such as SK chemicals for assets including J2H-1702 (MASH), J2H-2302 (IPF), J2H-2002 (NSCLC), J2H-1801 (multiple sclerosis), J2H-1802 (IBD), J2H-2104 (atopic dermatitis/osteoarthritis), and J2H-2301 (solid tumors).

Quantifiable outcome

  • J2H-1702 (MASH candidate): MRI-PDFF liver fat content decreased in dose-dependent and statistically significant manner vs. placebo; ALT liver function improved significantly in two high-dose groups; MRE-based liver stiffness decreased 30% or more in 10% of drug-treated patients vs. 0% in placebo; fibrosis biomarkers (Pro-C3, TIMP-1, PIIINP, HA, ELF) consistently decreased across all doses.
  • +2 more outcomes

Companies that use J2H Biotech

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

J2H Biotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

J2H Biotech partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered minor and core.

  • Korea Health Industry Development Institute (KHIDI)minorStrategic or Co-development Partner · 23 June 2026KHIDI organized partnering sessions between Korean biotechnology firms including J2H Biotech and AstraZeneca experts at the BIO International Convention in San Diego under Project NOVA. KHIDI plans to support follow-up communication to facilitate joint R&D, building on the K-Biopharma Next Bridge initiative launched with Korea's Ministry of Health and Welfare.
  • SK chemicals (SK케미칼)coreStrategic or Co-development Partner · 26 March 2026SK chemicals and J2H Biotech signed a memorandum of understanding to collaborate on new drug development focusing on MASH and IPF treatments. Both companies agreed to share research results and review data to determine the potential for joint development and commercialization. SK chemicals has been collaborating with J2H since 2021 through platform-based joint research for candidate discovery and strategic equity investment. The partnership expanded to potential co-development of J2H-1702 (MASH, Phase 2a completed) and J2H-2302 (IPF, preclinical).
  • Aptis (앱티스)coreStrategic or Co-development Partner · 22 October 2025Aptis and J2H Biotech entered a collaboration for ADC (Antibody-Drug Conjugate) new drug co-development. This partnership combines Aptis's ADC platform capabilities with J2H's small molecule and TPD technologies for innovative oncology drug development.
  • Samsung Seoul HospitalcoreStrategic or Co-development Partner · 15 July 2025Samsung Seoul Hospital and J2H Biotech entered a joint development agreement for BK virus (BKV) treatment targeting kidney transplant recipients and immunocompromised patients. This collaboration leverages clinical expertise and patient access to advance novel therapeutics for a rare, difficult-to-treat viral infection.
  • Huons (휴온스)minorStrategic or Co-development Partner · 3 July 2017J2H Biotech partnered with Huons for the development of a novel crystalline free base form of Tenofovir Disoproxil (generic version of Gilead's Viread). J2H provided the novel crystal form patent and the parties jointly conducted clinical studies, filing for product approval on the PMS expiration date. J2H successfully defended the patent against challenges from 11 competing pharmaceutical companies.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

J2H Biotech competitors and assessment

Company assessment

Direct peers

  • LegoChem Biosciences: South Korean biotech with a proprietary ADC and TPD platform (ConjuAll, TetraMAV) developing oncology therapeutics. Directly comparable to J2H on small-molecule discovery platform, TPD/ADC capability, and Korean biotech scale.
  • Hanmi Pharmaceutical: Major South Korean pharma with deep small-molecule pipelines and in-house CDMO/API manufacturing across multiple plants. Comparable to J2H in combining proprietary small-molecule R&D with integrated GMP manufacturing and B2B pharmaceutical services.
  • Bridge Biotherapeutics: South Korean clinical-stage biotech developing small-molecule therapies for fibrotic and inflammatory diseases, notably IPF. Closely comparable to J2H in indication overlap (IPF) and small-molecule, Korean clinical-stage biotech profile.
  • Gtreebio: South Korean biotech developing small-molecule therapeutics for ophthalmology and fibrotic diseases, co-founded by J2H's current CSO. Comparable to J2H on small-molecule modality, Korean biotech scale, and rare/intractable disease focus.
  • MedPacto: South Korean clinical-stage biotech focused on small-molecule oncology drug development. Comparable to J2H on small-molecule discovery, oncology pipeline programs (e.g., solid tumor candidates), and Korean clinical-stage biotech positioning.
  • Bioneer: South Korean biotech with molecular diagnostics and bio-therapeutic development plus in-house manufacturing. Comparable to J2H on combined R&D and manufacturing capabilities within a Korean mid-cap biotech profile.

Broad incumbents

  • Yuhan Corporation: Large South Korean pharmaceutical company with established small-molecule pipelines and active CDMO/API business. Comparable to J2H's CDMO plus proprietary drug development dual model, but at substantially greater scale and broader scope.
  • HK inno.N: Mid-to-large South Korean pharmaceutical company with small-molecule development and CDMO operations. Comparable to J2H on the integrated pharma-plus-CDMO structure, though operating at a much larger and more diversified scale.
  • Dong-A ST: Established South Korean pharmaceutical company with proprietary small-molecule drug pipelines and specialty manufacturing. Comparable to J2H on Korean pharma with proprietary small-molecule R&D plus manufacturing infrastructure, though at much greater commercial scale.

Emerging players

  • Aptis (partner): South Korean biotech with ADC platform capabilities partnered with J2H on ADC co-development. Comparable to J2H as a Korean emerging biotech collaborating on next-generation oncology modalities, with adjacent rather than directly overlapping technology.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

J2H Biotech compliance and trust

Trust signal

Compliance1 record

J2H Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

J2H Biotech leadership team

Management profile

Number of profiles

Profiles3 records

J2H Biotech funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

J2H Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about J2H Biotech

What does J2H Biotech do?

J2H Biotech is a bio-venture company that develops small-molecule drugs for the treatment of rare and intractable diseases using its proprietary OPTIFLEX AI-driven drug discovery platform, with seven candidates across MASH, IPF, NSCLC, multiple sclerosis, IBD, atopic dermatitis, osteoarthritis, and solid tumors. The company also operates two manufacturing facilities — a GMP-certified Ansan Plant for high-value API production and a multi-purpose Asan Plant — providing API manufacturing, patent circumvention, and CDMO (contract development and manufacturing organization) services to pharmaceutical clients under co-development and licensing partnerships.

Is J2H Biotech a public or private company?

J2H Biotech is a private company. It is classified as venture growth investor backed and is currently operating.

When was J2H Biotech founded?

J2H Biotech was founded in 2014. It employs 11 to 50 people.

Where is J2H Biotech based?

J2H Biotech is headquartered in Seongnam, South Korea, in the Asia region.

How does J2H Biotech make money?

Three revenue lines are on record. CDMO/Contract Manufacturing Services are the primary driver. The others are drug Development Licensing and Co-development and API Product Sales.

Who are J2H Biotech's main competitors?

Direct peers on record are LegoChem Biosciences, Hanmi Pharmaceutical, Bridge Biotherapeutics, Gtreebio, MedPacto and Bioneer. Broad incumbents are Yuhan Corporation, HK inno.N and Dong-A ST. Aptis (partner) is listed as an emerging player.

Does J2H Biotech have an API?

No public API is recorded for J2H Biotech.

What industry is J2H Biotech in?

J2H Biotech's product category is Pharmaceutical Drug Discovery and CDMO Services. Its primary akta.pro industry code is HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO, with a secondary code of HLAGAHAB, Small-Molecule API Commercial Manufacturing. Its NAICS code is 325412 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals